Drug Profile
BOS 589
Alternative Names: BOS-589; GSK-3352589Latest Information Update: 08 Dec 2022
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Boston Pharmaceuticals; GSK
- Class Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Irritable bowel syndrome
Most Recent Events
- 08 Dec 2022 No development reported - Phase-II for Irritable bowel syndrome in USA (PO)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome(In volunteers) in Australia (PO, Tablet)
- 04 Jun 2019 Phase-II clinical trials in Irritable bowel syndrome in USA (PO) (NCT03977155)